MondegarAI
Sio Capital Management, LLC

Q2 2024 · 13F-HR

Sio Capital Management, LLCholdings as filed

Filed 2024-08-14 · accession 0001214659-24-014597

$369.5M
Reported value
48
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
457669307INSMINSMED INC$91.3M24.7%1,362,700PUTSOLE
504922105LHLABCORP HOLDINGS INC$50.0M13.5%245,902CommonSOLE
879369106TFXTELEFLEX INCORPORATED$23.4M6.32%111,078CommonSOLE
98956P102ZBHZIMMER BIOMET HOLDINGS INC$16.9M4.56%155,304CommonSOLE
83175M205SNNSMITH & NEPHEW PLC$14.4M3.89%579,619CommonSOLE
695127100PCRXPACIRA BIOSCIENCES INC$13.0M3.53%455,500PUTSOLE
68622V106OGNORGANON & CO$12.6M3.41%608,096CommonSOLE
37733W204GSKGSK PLC$12.0M3.25%312,000CommonSOLE
21833P301CRBPCORBUS PHARMACEUTICALS HLDGS$10.2M2.76%225,165CommonSOLE
92243A200VXRTVAXART INC$9.9M2.67%14,764,991CommonSOLE
90240B106TYRATYRA BIOSCIENCES INC$9.6M2.60%600,294CommonSOLE
002824100ABTABBOTT LABORATORIES$9.3M2.52%89,500CommonSOLE
125523100CITHE CIGNA GROUP$8.9M2.40%26,786CommonSOLE
49177J102KVUEKENVUE INC$8.8M2.39%485,000CommonSOLE
254604101IRONDISC MEDICINE INC$8.7M2.34%192,000CommonSOLE
29479A108ERASERASCA INC$6.8M1.84%2,874,536CommonSOLE
09075X108BIODESIX INC$6.7M1.80%4,347,855CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$4.6M1.26%510,267CommonSOLE
00182C103ANIPANI PHARMACEUTICALS INC$4.6M1.24%71,740CommonSOLE
071705107BLCOBAUSCH PLUS LOMB CORP$4.4M1.19%302,710CommonSOLE
69353Y103PMVPPMV PHARMACEUTICALS INC$4.4M1.19%2,708,408CommonSOLE
98985Y108ZYMEZYMEWORKS INC$4.2M1.13%491,128CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$3.2M0.86%125,174CommonSOLE
03770N101APGEAPOGEE THERAPEUTICS INC$3.1M0.83%78,000CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$2.7M0.72%1,328,352CommonSOLE
60785L207MODULAR MED INC$2.4M0.66%1,539,352CommonSOLE
86150R107STOKSTOKE THERAPEUTICS INC$2.4M0.64%175,301CommonSOLE
29251M106ENTAENANTA PHARMACEUTICALS INC$2.3M0.62%177,004CommonSOLE
88427A107THIRD HARMONIC BIO INC$2.1M0.57%163,363CommonSOLE
67080N101NUVBNUVATION BIO INC$2.0M0.53%668,115CommonSOLE
82835W108SPRYARS PHARMACEUTICALS INC$1.9M0.50%217,864CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$1.8M0.49%778,924CommonSOLE
20451W101CMPSCOMPASS PATHWAYS PLC$1.8M0.48%293,417CommonSOLE
03969K108ARQTARCUTIS BIOTHERAPEUTICS INC$1.5M0.40%159,626CommonSOLE
98420X103ASNSUSDX4 PHARMACEUTICALS INC$1.4M0.39%2,499,800CommonSOLE
74065P101PRLDPRELUDE THERAPEUTICS INC$1.2M0.33%320,394CommonSOLE
03836J201APREAPREA THERAPEUTICS INC$1.1M0.30%276,603CommonSOLE
75382E109RAPT THERAPEUTICS INC$960,7500.26%315,000CommonSOLE
05338F306AVTXAVALO THERAPEUTICS INC$891,0810.24%71,458CommonSOLE
344174107FHTXFOGHORN THERAPEUTICS INC.$699,6140.19%121,672CommonSOLE
10170A100BOLDBOUNDLESS BIO INC$627,1640.17%162,058CommonSOLE
92337C203VSTMVERASTEM INC$397,5680.11%133,412CommonSOLE
B6S7WD106NYXHNYXOAH S A$354,3480.10%50,839CommonSOLE
65343E108NXTCEURNEXTCURE INC$206,7000.06%130,000CommonSOLE
04522R200ASLAN PHARMACEUTICALS LTD$76,2450.02%254,150CommonSOLE
44486Q111HUMAWHUMACYTE INC$70,4970.02%49,998CommonSOLE
77313F114RCKTWROCKET PHARMACEUTICALS INC$28,8800.01%400,000CommonSOLE
14171W111CAREMAX INC$2000.00%12,808CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.